Autonomic Dysfunction in Parkinson's Disease

Disease-a-Month

Volumn 53, Issue 5, 2007, Pages 265-274

  Dubow, Jordan S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AUTONOMIC DYSFUNCTION; CONSTIPATION; DISEASE ASSOCIATION; HUMAN; HYPERSALIVATION; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; REVIEW; SEXUAL DYSFUNCTION; SWEAT GLAND DISEASE; SYMPTOM; URINARY TRACT DISEASE;

ANTIPARKINSON AGENTS; AUTONOMIC NERVOUS SYSTEM DISEASES; CONSTIPATION; HUMANS; HYPERHIDROSIS; HYPOTENSION, ORTHOSTATIC; PARKINSON DISEASE; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; SIALORRHEA; URINATION DISORDERS;

EID: 34447500085     PISSN: 00115029     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.disamonth.2007.02.004     Document Type: Review

References (44)

1. Witjas T., Kaphan E., Azulay J.P., et al. Nonmotor fluctuations in Parkinson's disease. Neurology 59 (2002) 408-413
2. Turkka J.T., and Myllyla V.V. Sweating dysfunction in Parkinson's disease. Eur Neurol 26 (1987) 1-7
3. Hirashima F., Yokota, and Hayashi M. Sympathetic skin response in Parkinson's disease. Acta Neurol Scand 93 (1996) 127-132
4. Finazzi-Agro E., Peppe A., D'Amico A., et al. Effects of subthalamic nucleus stimulation on urodynamic findings in patients with Parkinson's disease. J Urol 169 (2003) 1388-1391
5. Jost W.H., and Eckardt V.F. Constipation in idiopathic Parkinson's disease. Scand J Gasterolenterol 7 (2003) 681-686
6. Allcock L.M., Ullyart K., Kenny R.A., et al. Frequency of orthostatic hypotension in a community based cohort of patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 75 (2004) 1470-1471
7. Turkka J., Suominen K., Tolonen U., et al. Selegiline diminishes cardiovascular autonomic responses in Parkinson's disease. Neurology 48 (1997) 662-667
8. Goldstein D.S. Dysautonomia in Parkinson's disease: neurocardiological abnormalities. Lancet Neurol 2 (2003) 669-676
9. Goldstein D.S., Pechnik S., Holmes C., et al. Association between supine hypertension and orthostatic hypotension in autonomic failure. Hypertension 42 (2003) 136-142
10. Lake C.R., Ziegler M.G., and Kopin I.J. Use of plasma norepinephrine for evaluation of sympathetic neuronal function in man. Life Sci 18 (1976) 1315-1325
11. Bouhaddi M., Vuillier F., Fortrat J.O., et al. Impaired Cardiovascular autonomic control in newly and long-term-treated patients with Parkinson's disease: involvement of L-dopa therapy. Auton Neurosci 116 (2004) 30-38
12. Fowler C.J. Urinary disorders in Parkinson's disease and multiple systems atrophy. Funct Neurol 16 (2001) 277
13. Araki I., Kitahara M., Oida T., et al. Voiding dysfunction and Parkinson's disease: urodynamic abnormalities and urinary symptoms. J Urol 164 (2000) 1640-1643
14. Stocchi F., Carbone A., Inghilleri, et al. Urodynamic and neuropyschological evaluation in Parkinson's disease and multiple systems atrophy. J Neurol Neurosurg Psychiatry 62 (1997) 507-511
15. Jankovic J., and Tolossa E. Parkinson's Disease and Movement Disorders. 4th ed (2002), Lippincott Williams & Wilkins, Philadelphia, PA
16. Ashraf W., Pfeiffer R.F., Park F., et al. Constipation in Parkinson's disease: objective assessment and response to psyllium. Mov Disord 12 (1997) 946-951
17. Kuroiwa Y., Wada T., and Tohgi H. Measurement of blood pressure and heart-rate variation while resting supine and standing for the evaluation of autonomic dysfunction. J Neurol 235 (1987) 65-68
18. Abbott R.D., Petrovitch H., White L.R., et al. Frequency of bowel movements and the risk of Parkinson's disease. Neurology 57 (2001) 456-462
19. Bassotti G., Maggio D., Battaglia E., et al. Manometric investigation of anorectal function in early and late stage Parkinson's disease. J Neurol Neurosurg Psychiatry 68 (2000) 768-770
20. Mathers S.E., Kempster P.A., Law P.J., et al. Anal sphincter dysfunction in Parkinson's disease. Arch Neurol 46 (1989) 1061-1064
21. Den Hartog Jager W.A. Sphingomyelin in Lewy inclusion bodies in Parkinson'd disease. Arch Neurol 21 (1969) 615-619
22. Forno L.S. The Lewy body in Parkinson's disease. Adv Neurol 45 (1986) 35-43
23. Kupsky W.J., Grimes M.M., Sweeting J., et al. Parkinson's disease and megacolon: concentric hyaline inclusions (Lewy bodies) in enteric ganglion cells. Neurology 37 (1987) 1253-1255
24. Ohama E., and Ikuta F. Parkinson's disease: distribution of Lewy bodies and monoamine neuron system. Acta Neuropathol 34 (1976) 311-319
25. Qualman S.J., Haupt H.M., Yang P., et al. Esophageal Lewy bodies associated with ganglion cell loss in achalasia: similarity to Parkinson's disease. Gastroenterology 87 (1984) 848-856
26. Wakabayashi K., Takahashi H., Ohame E., et al. Lewy bodies in the visceral autonomic nervous system in Parkinson's disease. Adv Neurol 60 (1993) 609-612
27. Edwards L., Quigley E.M.M., Hoffman R., et al. Gastrointestinal symptoms in Parkinson's disease: 18 month follow-up study. Mov Disord 8 (1993) 83-86
28. Wang S.J., Fuh J.L., Liao K.K., et al. Sympathetic skin response and R-R interval varation in Parkinson's disease. Mov Disord 8 (1993) 151-157
29. Edwards L.L., Pfeiffer R.F., Quigley E.M.M., et al. Gastrointestinal symptoms in Parkinson's disease. Mov Disord 6 (1991) 151-156
30. Soffer E.E., Metcalf A., Launspach J., et al. Misoprostol is effective treatment for patients with severe constipation. Dig Dis Sci 39 (1994) 929-933
31. Roarty T.P., Weber F., Soykan I., et al. Misoprostol in the treatment of chronic refractory constipation: results of a long-term open label trial. Aliment Pharmacol Ther 11 (1997) 1059-1066
32. Edwards L.L., Quigley E.M., Harned R.K., et al. Defecatory function in Parkinson's disease: response to apomorphine. Ann Neurol 33 (1993) 490-493
33. Eichhorn T.E., and Oertel W.H. Macrogol 3550/electrolyte improves constipation in Parkinson's disease and multi system atrophy. Mov Disord 16 (2001) 1176-1177
34. Wermuth C., and Stenager E. Sexual problems in young patients with Parkinson's disease. Acta Neurol Scand 91 (1995) 453-455
35. Hussain I.F., Brady C.M., Swinn M.J., et al. Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension. J Neurol Neurosurg Psychiatry 71 (2001) 371-374
36. Heaton J. Central neuropharmacological agents and mechanism in erectile dysfunction: the role of dopamine. Neurosci Behav Rev 24 (2000) 561-569
37. Raffaele R., and Vecchio I. Efficacy and safety of fixed-dose oral sildenafil in the treatment of sexual dysfunction in depressed patients with idiopathic Parkinson's disease. Eur Urol 41 (2002) 382-386
38. Dohanka M., and Kanovsky P. Pergolide mesylate can improve sexual dysfunction in patients with Parkinson's disease: the results of an open, prospective, 6-month follow-up. Eur J Neurol (2004) 483-488
39. Mano Y., Nakamuro T., Takayanagi T., et al. Sweat function in Parkinson's disease. J Neurol 241 (1994) 573-576
40. Sage J.I., and Mark M.H. Drenching sweats as an off phenomenon in Parkinson's disease: treatment and relation to plasma levodopa profile. Ann Neurol 37 (1995) 120-122
41. Bagheri H., Damase-Michel C., Lapeyre-Mestre M., et al. A study of salivary secreation in Parkinson's disease. Clin Neuropharmacol 22 (1999) 213-215
42. Johnston B.T., Li Q., Castell J.A., et al. Swallowing and esophageal function in Parkinson's disease. Am J Gastroenterol 90 (1995) 1741-1746
43. Ondo W.G., Hunter C., and Moore W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease. Neurology 62 (2004) 37-40
44. Mancini F., Zangaglia R., Cristina S., et al. Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism. Mov Disord 18 (2003) 685-688